BMT Clinical Trials Network

What is memoblast and what is its approved clinical indication?

Memoblast (remestemcel‑L, marketed as Ryoncil®/RYONCIL®/Ryoncil in Mesoblast materials) is an allogeneic bone‑marrow derived mesenchymal stromal cell therapy. The U.S. FDA granted approval for remeste...